157 related articles for article (PubMed ID: 31480599)
21. Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy.
Wang S; Zhang J; Wang Y; Chen M
Nanomedicine; 2016 Feb; 12(2):411-20. PubMed ID: 26711968
[TBL] [Abstract][Full Text] [Related]
22. CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer.
Agrawal S; Dwivedi M; Ahmad H; Chadchan SB; Arya A; Sikandar R; Kaushik S; Mitra K; Jha RK; Dwivedi AK
Nanomedicine; 2018 Feb; 14(2):327-337. PubMed ID: 29129754
[TBL] [Abstract][Full Text] [Related]
23. Mitochondria Targeting and Destabilizing Hyaluronic Acid Derivative-Based Nanoparticles for the Delivery of Lapatinib to Triple-Negative Breast Cancer.
Lee SY; Cho HJ
Biomacromolecules; 2019 Feb; 20(2):835-845. PubMed ID: 30566834
[TBL] [Abstract][Full Text] [Related]
24. Quantification and characterization of enzymatically produced hyaluronan with fluorophore-assisted carbohydrate electrophoresis.
Kooy FK; Ma M; Beeftink HH; Eggink G; Tramper J; Boeriu CG
Anal Biochem; 2009 Jan; 384(2):329-36. PubMed ID: 18948072
[TBL] [Abstract][Full Text] [Related]
25. Use of 15N-NMR to resolve molecular details in isotopically-enriched carbohydrates: sequence-specific observations in hyaluronan oligomers up to decasaccharides.
Blundell CD; DeAngelis PL; Day AJ; Almond A
Glycobiology; 2004 Nov; 14(11):999-1009. PubMed ID: 15215231
[TBL] [Abstract][Full Text] [Related]
26. Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer.
Wang S; Shao M; Zhong Z; Wang A; Cao J; Lu Y; Wang Y; Zhang J
Drug Deliv; 2017 Nov; 24(1):1791-1800. PubMed ID: 29172759
[TBL] [Abstract][Full Text] [Related]
27. A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer.
Chen C; Shen M; Liao H; Guo Q; Fu H; Yu J; Duan Y
J Nanobiotechnology; 2021 Feb; 19(1):55. PubMed ID: 33632232
[TBL] [Abstract][Full Text] [Related]
28. Differently complex oligosaccharides can be easily identified by matrix-assisted laser desorption and ionization time-of-flight mass spectrometry directly from a standard thin-layer chromatography plate.
Nimptsch K; Süss R; Riemer T; Nimptsch A; Schnabelrauch M; Schiller J
J Chromatogr A; 2010 Jun; 1217(23):3711-5. PubMed ID: 20434160
[TBL] [Abstract][Full Text] [Related]
29. Enzymatically stable unsaturated hyaluronan-derived oligosaccharides with selective cytostatic properties.
Klejch T; Buffa R; Šimek M; Nešporová K; Exnerová A; Bednařík J; Brandejsová M; Vágnerová H; Fiala F; Velebný V
Carbohydr Polym; 2024 Jul; 336():122129. PubMed ID: 38670770
[TBL] [Abstract][Full Text] [Related]
30. Novel methods for the preparation and characterization of hyaluronan oligosaccharides of defined length.
Mahoney DJ; Aplin RT; Calabro A; Hascall VC; Day AJ
Glycobiology; 2001 Dec; 11(12):1025-33. PubMed ID: 11805075
[TBL] [Abstract][Full Text] [Related]
31. Leucinostatins from
Kil YS; Risinger AL; Petersen CL; Mooberry SL; Cichewicz RH
J Nat Prod; 2020 Jun; 83(6):2010-2024. PubMed ID: 32510949
[TBL] [Abstract][Full Text] [Related]
32. Co-Delivery of Hesperetin and Cisplatin via Hyaluronic Acid-Modified Liposome for Targeted Inhibition of Aggression and Metastasis of Triple-Negative Breast Cancer.
Wang X; Song Y; Yu L; Xue X; Pang M; Li Y; Luo X; Hua Z; Lu C; Lu A; Liu Y
ACS Appl Mater Interfaces; 2023 Jul; 15(29):34360-34377. PubMed ID: 37432741
[TBL] [Abstract][Full Text] [Related]
33. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
34. The use of HA oligosaccharide-loaded nanoparticles to breach the endogenous hyaluronan glycocalyx for breast cancer therapy.
Yang C; Liu Y; He Y; Du Y; Wang W; Shi X; Gao F
Biomaterials; 2013 Sep; 34(28):6829-38. PubMed ID: 23764114
[TBL] [Abstract][Full Text] [Related]
35. Vitamin D regulation of HAS2, hyaluronan synthesis and metabolism in triple negative breast cancer cells.
Narvaez CJ; Grebenc D; Balinth S; Welsh JE
J Steroid Biochem Mol Biol; 2020 Jul; 201():105688. PubMed ID: 32360595
[TBL] [Abstract][Full Text] [Related]
36. Hyaluronan oligosaccharides as a potential anticancer therapeutic.
Toole BP; Ghatak S; Misra S
Curr Pharm Biotechnol; 2008 Aug; 9(4):249-52. PubMed ID: 18691085
[TBL] [Abstract][Full Text] [Related]
37. Thin-layer chromatography of hyaluronate oligosaccharides.
Shimada E; Matsumura G
J Biochem; 1984 Sep; 96(3):721-5. PubMed ID: 6501262
[TBL] [Abstract][Full Text] [Related]
38. Functionalized derivatives of hyaluronic acid oligosaccharides: drug carriers and novel biomaterials.
Pouyani T; Prestwich GD
Bioconjug Chem; 1994; 5(4):339-47. PubMed ID: 7948100
[TBL] [Abstract][Full Text] [Related]
39. KR-33028, a potent inhibitor of the Na
Amith SR; Wilkinson JM; Fliegel L
Biochem Pharmacol; 2016 Oct; 118():31-39. PubMed ID: 27521504
[TBL] [Abstract][Full Text] [Related]
40. Comparative proteomic profiling of triple-negative breast cancer reveals that up-regulation of RhoGDI-2 is associated to the inhibition of caspase 3 and caspase 9.
Muñiz Lino MA; Palacios-Rodríguez Y; Rodríguez-Cuevas S; Bautista-Piña V; Marchat LA; Ruíz-García E; Astudillo-de la Vega H; González-Santiago AE; Flores-Pérez A; Díaz-Chávez J; Carlos-Reyes Á; Álvarez-Sánchez E; López-Camarillo C
J Proteomics; 2014 Dec; 111():198-211. PubMed ID: 24768906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
